Recent news on Vantas

Indevus to Present at the 2007 FBR Growth Conference  -  May 23, 2007
Earthtimes.orgThe Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male

Alkermes and Indevus Announce Initiation of Phase 2a Clinical ...  -  26 Apr 2007
PipelineReview.com (press release),The Company’s marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male

Indevus Announces Submission of Supplemental NDA to Reintroduce ...  -  Apr 19, 2007
PipelineReview.com (press release),The Company's marketed products include SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, and DELATESTRYL(R) to treat male

Indevus and Valera Announce Completion of Merger  -  Apr 18, 2007
PharmaLive.com (press release),VANTAS(R), a patent protected once-per-year implant currently marketed by Valera for the palliative treatment of advanced prostate cancer, employs this drug

Indevus Reports That Interim Review of NEBIDO(R) Phase III Data ...  -  27 Mar 2007
PipelineReview.com (press release),VANTAS(R), a patent protected once-per-year implant currently marketed by Valera for the palliative treatment of advanced prostate cancer, employs this drug

BIOALLIANCE PHARMA BioAlliance Pharma sets up European Joint ...  -  Mar 7, 2007
La Tribune.fr,Spepharm acquired from Valera Pharmaceuticals Inc. the exclusive European marketing and distribution rights to Vantas®, a 12-month implant for the

Valera Pharmaceuticals Reports 2006 Financial Results  -  Feb 22, 2007
SYS-CON Media,Net product sales of VANTAS during the fourth quarter of 2006 were approximately $3.2 million, primarily representing 2324 units sold in the United States

EU panel backs Novartis' mock-up pandemic flu vaccine  -  Feb 23, 2007
MarketWatchThe Committee started a referral procedure for Vantas 50 mg implant (histrelin acetate), from Valera Pharmaceuticals Ltd, Ireland.

Indevus Pharmaceuticals Announces First Quarter Fiscal 2007 ...  -  Feb 7, 2007
Earthtimes.orgIndevus and Valera announced that they entered into a co-promotion agreement under which Indevus' sales force will co-promote VANTAS(R) in the United States

Indevus Pharmaceuticals Announces First Quarter Fiscal 2007 ...  -  Feb 7, 2007
PharmaLive.com (press release),Indevus began co-promoting VANTAS on January 15,. obstructive pulmonary disease (COPD). The announcement followed the. successful phase I study in healthy

Valera Pharmaceuticals Commences Studies of a Novel Biodegradable ...  -  Feb 6, 2007
Genetic Engineering News (press release),VANTAS(R), a patent protected once-per-year implant currently marketed by Valera for the palliative treatment of advanced prostate cancer, employs this drug

Risa Bernstein, Agency Co-Founder, Returns to Flashpoint Medica  -  Jan 17, 2007
PharmaLive.com (press release),...a hormone replacement patch, Valera for Valstar (Valrubicin) a bladder cancer agent, Vantas for prostate cancer and Supprelin for precocious puberty.

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  Dec 13, 2006
PipelineReview.com (press release),The Company markets VANTAS(R) for advanced prostate cancer and has multiple products in clinical development including SUPPRELIN(R)-LA for central

Indevus Pharmaceuticals to Acquire Valera Pharmaceuticals  -  Dec 12, 2006
Yahoo! News (press release)The Company markets VANTAS® for advanced prostate cancer and has multiple products in clinical development including SUPPRELIN®-LA for central precocious

Indevus Pharma to Buy Valera for $120M  -  Dec 12, 2006
Houston Chronicle,The two companies also entered into a co-promotion agreement under which Indevus' sales force will co-promote Vantas, a treatment for advanced prostate

Indevus to buy Valera for $120 million  -  Dec 13, 2006
Pharmaceutical Business ReviewThe company has multiple products in clinical development including Vantas for prostate cancer, Supprelin-LA for the treatment of central precocious puberty

Indevus Procures Valera for $120M  -  Dec 12, 2006
Genetic Engineering News (press release),Indevus anticipates co-promotion of Vantas to begin in January 2007. According to the deal, Indevus expects to earn royalties of 13.5% on sales of Vantas up

Valera Jumps on Buyout Deal  -  Dec 12, 2006
BusinessWeekCranbury (NJ)-based Valera markets Vantas, a hormone suppression implant used in the treatment of advanced prostate cancer. Designed to slow tumor growth,

Indevus Pharma to buy Valera for $120M  -  Dec 12, 2006
Eyewitness News,Third-quarter sales of Vantas declined 21 percent, reflecting decreases in Medicare reimbursement rates plus pressure on unit shipments because of price

Indevus will buy New Jersey firm  -  Dec 12, 2006
Boston Globe,Valera's focus is on urology and endocrinology products; one product on the market is Vantas for advanced prostate cancer. "The acquisition of Valera firmly

UPDATE 1-Indevus Pharmaceuticals to buy Valera for $120 mln  -  Dec 12, 2006
ReutersIndevus also agreed to co-promote Valera's advanced prostate cancer implant, Vantas, in the US Indevus will get royalties of 13.5 percent on sales of up to

Valera Pharmaceuticals Acquired in $120 Million Stock Deal  -  Dec 12, 2006
Business New Jersey (subscription),Its products include Vantas for the treatment of advanced prostate cancer. Indevus makes drugs such as Sanctura, which is a treatment for overactive bladder

Indevus buys Valera in $120M stock deal  -  Dec 12, 2006
United Press InternationalValera develops treatments in the areas of urology and endocrinology, including Vantas for advanced prostate cancer and Supprelin-LA for central precocious

Indevus Buyout of Valera to Grow Earnings  -  Dec 18, 2006
Seeking Alpha,Valera also sells Vantas, a 30 X 3.5 mm polymer cylinder that slowly leaches Histrelin acetate, a luteinizing hormone releasing hormone [LHRH],

National Patent Development Announces Proposed Valera ...  -  Dec 14, 2006
Business Wire (press release),Valera markets VANTAS for advanced prostate cancer and has multiple products in clinical development including SUPPRELIN-LA for central precocious puberty.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional